Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
A number of age-related physiological changes contribute to an increased risk of toxicity of cancer chemotherapy in the elderly. One of the most important of these changes is the progressive decline in renal function with aging. We sought to determine the association between calculated creatinine clearance (CLCR) and grade 3 or 4 toxicities during adjuvant chemotherapy in women ≥65 years of age with breast cancer.
Design and methods
We identified 1405 patients ≥65 years of age who had been treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. Patients were included in this analysis if they had stage I–III breast cancer and had received adjuvant chemotherapy. Patients were excluded if they had a prior history of breast cancer or chemotherapy, or had no baseline creatinine value available for review.
The 126 patients who met our criteria had received either cyclophos-phamide, methotrexate and fluorouracil (CMF) [n = 65, mean age 71, range 65–78] or an anthracycline-based regimen (n = 61, mean age 69, range 65–79). The majority of patients (97%) had a normal creatinine. CLCR, as calculated by the Cockcroft-Gault and Jeliffe formulas, decreased with increasing age (increased age associated with decreased Cockcroft-Gault [p = 0.02]; increased age associated with decreased Jeliffe [p < 0.01]). In multivariate analysis, after controlling for age and co-morbidity, a CLCR <50 mL/min by the Cockcroft-Gault formula was associated with an increased risk of fever and neutropenia (odds ratio [OR] 3.60; 95% CI 1.00, 12.94; p = 0.05) and a CLCR <50 mL/min by the Jeliffe formula was associated with a trend towards an increased risk of fever and neutropenia (OR 3.30; 95% CI 0.91, 12.33; p = 0.07), grade 3 or 4 haematological toxicity (OR 2.43; 95% CI 0.90, 6.55; p = 0.08), and need for erythropoietin (OR 4.15; 95% CI 0.81, 2.99; p = 0.09). An increase in creatinine (as a continuous variable) was associated with a trend towards an increased risk of grade 3 or 4 haematological toxicity (OR 5.81; 95% CI 0.96, 35.33; p = 0.06).
In this cohort of older breast cancer patients, a decreased CLCR and increased creatinine was associated with an increased risk of fever and neutropenia or haematological toxicity. CLCR should be considered when determining chemotherapy dosage in the elderly.
- Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005; 55(1): 10–30 CrossRef
- Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80(7): 1273–83 CrossRef
- Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85(19): 1580–4 CrossRef
- Busch E, Kemeny M, Fremgen A, et al. Patterns of breast cancer care in the elderly. Cancer 1996; 78(1): 101–11 CrossRef
- Bergman L, Dekker G, van Leeuwen FE, et al. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer 1991; 67(9): 2227–34 CrossRef
- Newschaffer CJ, Penberthy L, Desch CE, et al. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996; 156(1): 85–90 CrossRef
- Yancik R, Ries LG, Yates JW. Breast cancer in aging women: a population-based study of contrasts in stage, surgery, and survival. Cancer 1989; 63(5): 976–81 CrossRef
- Hillner BE, Penberthy L, Desch CE, et al. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat 1996; 40(1): 75–86 CrossRef
- Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996; 88(11): 716–26 CrossRef
- Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002; 20(24): 4636–42 CrossRef
- Hurria A, Leung D, Trainor K, et al. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 2003; 46(2): 121–6 CrossRef
- Vestal RE. Aging and pharmacology. Cancer 1997; 80(7): 1302–10 CrossRef
- Grochow LB, Colvin M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1979; 4: 380–96 CrossRef
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83 CrossRef
- Lichtman SM, Skirvin JA, Vemulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 2003; 46: 104–14 CrossRef
- Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004; 40: 333–42 CrossRef
- Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2(12): 1404–13
- Rimon E, Kagansky N, Cojocaru L, et al. Can creatinine clearance be accurately predicted by formulae in octogenarian inpatients? Q J Med 2004; 97: 281–7 CrossRef
- Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2003; 38: 73–7 CrossRef
- Du XL, Key CR, Osborne C, et al. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 2003 Jan 21; 138(2): 90–7
- Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer
Drugs & Aging
Volume 22, Issue 9 , pp 785-791
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors